GeneSegues Therapeutics

GeneSegues Therapeutics is a private U.S. biotechnology company developing non-viral sub-50 nanometer nanocapsule delivery technology for nucleic acid medicines. The company originated from University of Minnesota research and has focused on targeted delivery of RNAi therapeutics and other gene-based payloads to tumors and other hard-to-reach tissues. Its lead historical oncology program, GS-10, used a tenfibgen-coated nanocapsule to deliver RNAi against casein kinase 2 for solid tumors including head and neck cancer. More recently, the company has presented its platform through the Surtovol Laboratories brand, emphasizing partnership-oriented applications in next-generation gene therapy delivery, including RNA, plasmid DNA, and related payloads. Available evidence suggests the company remains legally active, but its drug pipeline appears to remain preclinical and development visibility is limited.